VHL and nonpapillary renal cell carcinoma: PT-2399, a 2,3-dihydro-1H-inden-4-yl-oxy derivative (Peloton Therapeutics, Inc., now Merck, Kenilworth, NJ, USA), and PT-2385 specifically inhibit HIF-2α-ARNT dimerization, leading to anti-angiogenic influences in human primary and metastatic VHL-defective ccRCC cell xenografted mouse models [175,177,178,179].